Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Comprehensive clinico-molecular profile and efficacy of anti-HER2 therapy for HER2-amplified biliary tract cancer.
Authors
Kanae Inoue
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Kanae Inoue , Yoshiaki Nakamura , Bennett Caughey , Binbin Zheng-Lin , Makoto Ueno , Masayuki Furukawa , Yasuyuki Kawamoto , Shinji Itoh , Kumiko Umemoto , Kentaro Sudo , Taroh Satoh , Nobumasa Mizuno , Takeshi Kajiwara , Takao Fujisawa , Hideaki Bando , Takayuki Yoshino , John H Strickler , Tanios S. Bekaii-Saab , Chigusa Morizane , Masafumi Ikeda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 544)
DOI
10.1200/JCO.2024.42.3_suppl.544
Abstract #
544
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterizing outcomes of ERBB2-amplified biliary tract cancer.
First Author: Daniel Aaron Fox
Poster
2023 ASCO Annual Meeting
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.
First Author: Subotheni Thavaneswaran
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2021 ASCO Annual Meeting
Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers.
First Author: Sunyoung S. Lee